BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Holst F. Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate. World J Clin Oncol 2016; 7(2): 160-173 [PMID: 27081639 DOI: 10.5306/wjco.v7.i2.160]
URL: https://www.wjgnet.com/2218-4333/full/v7/i2/160.htm
Number Citing Articles
1
Tomás Reinert, Guilherme Portela Coelho, Jovana Mandelli, Edinéia Zimermann, Facundo Zaffaroni, José Bines, Carlos Henrique Barrios, Marcia Silveira Graudenz. Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from BrazilJournal of Oncology 2019; 2019: 1 doi: 10.1155/2019/1947215
2
Luiz Gustavo de Almeida Chuffa, Luiz Antonio Lupi-Júnior, Aline Balandis Costa, João Paulo de Arruda Amorim, Fábio Rodrigues Ferreira Seiva. The role of sex hormones and steroid receptors on female reproductive cancersSteroids 2017; 118: 93 doi: 10.1016/j.steroids.2016.12.011
3
Anna Kawiak, Anna Kostecka. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine TherapyCancers 2022; 14(2): 279 doi: 10.3390/cancers14020279
4
Ahmed Basudan, Nolan Priedigkeit, Ryan J. Hartmaier, Ethan S. Sokol, Amir Bahreini, Rebecca J. Watters, Michelle M. Boisen, Rohit Bhargava, Kurt R. Weiss, Maria M. Karsten, Carsten Denkert, Jens-Uwe Blohmer, Jose P. Leone, Ronald L. Hamilton, Adam M. Brufsky, Esther Elishaev, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast CancerMolecular Cancer Research 2019; 17(2): 457 doi: 10.1158/1541-7786.MCR-18-0946
5
Asaad Azarnezhad, Mina Tabrizi, Morteza Atri, Parvin Mehdipour. ESR1 Gene Amplification in an Iranian Population with Early Onset Invasive Ductal Breast Carcinoma Breast Cancer Management 2018; 7(2) doi: 10.2217/bmt-2017-0018
6
Lan Cao, Ahmed Basudan, Matthew J. Sikora, Amir Bahreini, Nilgun Tasdemir, Kevin M. Levine, Rachel C. Jankowitz, Priscilla F. McAuliffe, David Dabbs, Sue Haupt, Ygal Haupt, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich, Jennifer M. Atkinson. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinomaCancer Letters 2019; 461: 21 doi: 10.1016/j.canlet.2019.06.011
7
Irina Gaynanova, Tianying Wang. Sparse quadratic classification rules via linear dimension reductionJournal of Multivariate Analysis 2019; 169: 278 doi: 10.1016/j.jmva.2018.09.011
8
Sarah R. Hosford, Kevin Shee, Jason D. Wells, Nicole A. Traphagen, Jennifer L. Fields, Riley A. Hampsch, Arminja N. Kettenbach, Eugene Demidenko, Todd W. Miller. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancerMolecular Oncology 2019; 13(8): 1778 doi: 10.1002/1878-0261.12528
9
Piera Rizzolo, Anna Sara Navazio, Valentina Silvestri, Virginia Valentini, Veronica Zelli, Ines Zanna, Giovanna Masala, Simonetta Bianchi, Marco Scarnò, Stefania Tommasi, Domenico Palli, Laura Ottini. Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancersOncotarget 2016; 7(45): 74097 doi: 10.18632/oncotarget.12272
10
Christian F. Singer, Frederik Holst, Stefan Steurer, Eike C. Burandt, Sigurd F. Lax, Raimund Jakesz, Margaretha Rudas, Herbert Stöger, Richard Greil, Guido Sauter, Martin Filipits, Ronald Simon, Michael Gnant. Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast CancerClinical Cancer Research 2022; 28(18): 4112 doi: 10.1158/1078-0432.CCR-21-4328
11
Carlos Martínez-Pérez, Arran K Turnbull, J Michael Dixon. The evolving role of receptors as predictive biomarkers for metastatic breast cancerExpert Review of Anticancer Therapy 2019; 19(2): 121 doi: 10.1080/14737140.2019.1552138
12
Chi-Cheng Huang, Yi-Fang Tsai, Chun-Yu Liu, Ta-Chung Chao, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Jen-Hwey Chiu, Chih-Yi Hsu, Ling-Ming Tseng. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analysesBMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-07931-4
13
Hitisha K. Patel, Teeru Bihani. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatmentPharmacology & Therapeutics 2018; 186: 1 doi: 10.1016/j.pharmthera.2017.12.012
14
Stéphanie L. Gaillard, Kaitlyn J. Andreano, Laurie M. Gay, Meghan Steiner, Matthew S. Jorgensen, Brittany Anne Davidson, Laura J. Havrilesky, Angeles Alvarez Secord, Fidel A. Valea, Gerardo Colon-Otero, Deborah A. Zajchowski, Ching-Yi Chang, Donald P. McDonnell, Andrew Berchuck, Julia A. Elvin. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapiesGynecologic Oncology 2019; 154(1): 199 doi: 10.1016/j.ygyno.2019.04.010
15
Anna Nagel, Jolanta Szade, Mariola Iliszko, Julia Elzanowska, Marzena Welnicka-Jaskiewicz, Jaroslaw Skokowski, Grzegorz Stasilojc, Jacek Bigda, Rafal Sadej, Anna Zaczek, Aleksandra Markiewicz. Clinical and Biological Significance of ESR1 Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer PatientsInternational Journal of Molecular Sciences 2019; 20(8): 1881 doi: 10.3390/ijms20081881
16
Frederik Holst, Christian F. Singer. ESR1 -Amplification-Associated Estrogen Receptor α Activity in Breast CancerTrends in Endocrinology & Metabolism 2016; 27(11): 751 doi: 10.1016/j.tem.2016.08.002
17
Wenbin Ma, Sara Herrera-Rodriguez, Hector Martinez-Valdez. Personalized Pathway-Activated Systems Imaging in Oncology2017; : 127 doi: 10.1007/978-981-10-3349-0_7
18
Tomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, Leonardo Roberto Silva, Ana Elisa Ribeiro da Silva, Camila Annicchino de Andrade, Maria Beatriz de Paula Leite Kraft, Guilherme Portela Coelho, Jovana Mandelli, Monique Binotto, Cesar Cabello, Geisilene Russano de Paiva Silva, José Bines, Carlos H. Barrios, Matthew J. Ellis, Marcia Silveira Graudenz. ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor TherapyFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00342
19
Azadeh Nasrazadani, Roby A. Thomas, Steffi Oesterreich, Adrian V. Lee. Precision Medicine in Hormone Receptor-Positive Breast CancerFrontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00144
20
Yasmin M. Vasquez, W. Lee Kraus. Estrogen Receptor and Breast CancerCancer Drug Discovery and Development 2019; : 95 doi: 10.1007/978-3-319-99350-8_5